Trial Profile

Effect on Contrast Induced Acute Kidney Injury of APX-115 in Subjects Undergoing Percutaneous Coronary Intervention A Randomized, Double-blind, Parallel Group, Multicenter, Multi-national Trial

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Jun 2025 According to an AptaBio Therapeutics media release, company expects completing patient administration in the second half of 2025.
16 Oct 2023 According to an AptaBio Therapeutics media release, this trial will be conducted at approximately 15 clinical trial institutions in Korea and the United States, and 13 hospitals, including Samsung Seoul Hospital, have been confirmed in Korea.
16 Oct 2023 According to an AptaBio Therapeutics media release, company received Phase 2 IND approval for contrast agent-induced acute kidney injury (CI-AKI) for 'Isuzynaxib (APX-115)' from U.S. FDA in January and the Korean Ministry of Food and Drug Safety in May.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com